SEC Tracker
Get the app
ICCC · XBRL financial data

ImmuCell financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (ICCC's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue———17,47226,493—
Revenue from contracts with customers15,34219,24318,56817,47226,49327,644
Cost of revenue————18,55216,199
Cost of goods and services sold8,47910,58710,91913,60218,552—
Gross profit6,8638,6567,6493,8697,94111,445
Research and development4,3554,1694,4944,3953,8993,042
General and administrative1,7211,7262,2642,1342,2173,201
Total operating expenses8,2438,3999,9489,6179,5819,796
Other operating income (expense)—327187———
Operating income (loss)(1,380)257(2,299)(5,748)(1,640)1,649
Interest income————78159
Interest expense—314349476569493
Other income (expense)348(327)(187)(22)——
Income tax expense (benefit)(10)9851012
Net income (loss)(1,022)(78)(2,494)(5,775)(2,157)(1,040)
Earnings per share, basic USD per share(0.14)(0.01)(0.32)(0.75)(0.26)(0.12)
Earnings per share, diluted USD per share(0.14)(0.01)(0.32)(0.75)(0.26)(0.12)
Weighted average shares, basic thousands of shares7,2137,5927,7457,7488,1679,026
Weighted average shares, diluted thousands of shares7,2137,5927,7457,7488,1679,026

Balance sheet

CSV

Fiscal years (ICCC's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents6,95010,1855,7929793,7583,807
Short-term investments996—————
Accounts receivable1,7972,6941,7592,1853,7713,419
Inventory2,0933,0906,0397,8127,1139,267
Prepaid and other current assets321295406494401452
Total current assets12,15716,26513,99511,47015,04316,945
Property and equipment, net26,75526,89428,44227,57625,34921,075
Right-of-use asset1,2201,1092,1954,5714,5614,380
Goodwill969696969696
Total assets40,35044,46644,86143,80845,10042,532
Current portion of long-term debt————1,4981,610
Total current liabilities2,2112,5343,0724,1974,4123,978
Long-term debt————9,0417,489
Lease liability, non-current1,1351,0272,2174,0774,1294,010
Total liabilities12,08311,88914,48118,81517,58215,477
Accumulated deficit(3,660)(3,739)(6,232)(12,007)(14,164)(15,204)
Total stockholders' equity28,26632,57730,38024,99327,51827,055
Total liabilities and equity40,35044,46644,86143,80845,10042,532
Common shares outstanding (cover page) thousands of shares7,2217,7437,7477,7518,9839,047

Cash flows

CSV

Fiscal years (ICCC's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(1,022)(78)(2,494)(5,775)(2,157)(1,040)
Stock-based compensation253144266369326296
Depreciation and amortization———2,7402,7302,784
Net cash from operating activities1,316954(1,544)(4,674)3582,475
Purchases of property and equipment4,0732,6093,9751,8934661,250
Net cash from investing activities(2,570)(1,597)(3,964)(1,890)(461)(1,214)
Proceeds from issuing common stock39165——4,648349
Net cash from financing activities1,9113,8791,1141,7512,883(1,212)
Net change in cash————2,77949

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Immucell8,8607,1863,019*9.1M— 10-QJun 30, 2026
Fitlife Brands1,089not reported3,635*9.4M— 10-QJun 30, 2026
Cue Biopharma17,3927,877(29,004)*7.3M0.6 quarters 10-QJun 30, 2026
Cyanotech6496,976108*7.4M— 10-QSep 30, 2025
Avalo Therapeutics85,382not reported(19,988)*53.6M20.0 quarters 10-QJun 30, 2026
Precision Biosciences81,6980(15,132)*27.9M6.1 quarters 10-QSep 30, 2026
Opus Genetics88,812755(11,950)*83.2M7.4 quarters 10-QJun 30, 2026
Acumen Pharmaceuticals53,075not reported(26,653)*72.3M3.4 quarters 10-QSep 30, 2026
iBio56,3950*(6,228)*64.3M14.1 quarters 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.